Studies have indicated that NSCLC patients with concurrent EGFR/RB1/TP53 mutations are more prone to transform into SCLC (31), especially those with a high frequency of AID/APOBEC mutations and genomic amplifications. This evidence concerns the gene EGFR and non-small cell lung carcinoma.